De novo Synthesis of Chiral 3,4-Dihydroquinazolines via One-Pot Enantioselective Ugi-Azide/Cyclization Sequences

Background and Originality Content,3,4-Dihydroquinazoline frameworks have frequently been encountered in natural products and bioactive molecules.In the past decades,these key structures prompted the development of creative pharmaceuticals owing to their prominent biological properties,including trypanothione reductase(TryR)inhibitor,Hepatitis B virus(HBV)inhibitive activities,anticancer activities,etc.(Scheme 1A).[1]Notably,the chirality of the C4 atom is crucial for drug design.For example,the DPC-083 is a potent reverse transcriptase inhibitor for the treatment of HIV infection but the undesired enantiomers exhibit virtually no activity.[ia]Therefore,developing synthetic methods for innovative chiral 4-substituted 3,4-dihydroquinazolines is significant and essential for drug discovery.